Skip to main content
PMC home page
CNS Drug Reviews logoLink to CNS Drug Reviews
. 2007 Apr 24;13(1):21–42. doi: 10.1111/j.1527-3458.2007.00001.x

Lacosamide: A Review of Preclinical Properties

Bettina K Beyreuther 1, Joachim Freitag 1, Cara Heers 1, Niels Krebsfänger 1, Ute Scharfenecker 1, Thomas Stöhr 1
PMCID: PMC6494128  PMID: 17461888

ABSTRACT

Lacosamide (LCM), (SPM 927, (R)‐2‐acetamido‐N‐benzyl‐3‐methoxypropionamide, previously referred to as harkoseride or ADD 234037) is a member of a series of functionalized amino acids that were specifically synthesized as anticonvulsive drug candidates. LCM has demonstrated antiepileptic effectiveness in different rodent seizure models and antinociceptive potential in experimental animal models that reflect distinct types and symptoms of neuropathic as well as chronic inflammatory pain. Recent results suggest that LCM has a dual mode of action underlying its anticonvulsant and analgesic activity. It was found that LCM selectively enhances slow inactivation of voltage‐gated sodium channels without affecting fast inactivation. Furthermore, employing proteomic affinity‐labeling techniques, collapsin‐response mediator protein 2 (CRMP‐2 alias DRP‐2) was identified as a binding partner. Follow‐up experiments confirmed a functional interaction of LCM with CRMP‐2 in vitro. LCM did not inhibit or induce a wide variety of cytochrome P450 enzymes at therapeutic concentrations. In safety pharmacology and toxicology studies conducted in mice, rats, rabbits, and dogs, LCM was well tolerated. Either none or only minor side effects were observed in safety studies involving the central nervous, respiratory, gastrointestinal, and renal systems and there is no indication of abuse liability. Repeated dose toxicity studies demonstrated that after either intravenous or oral administration of LCM the adverse events were reversible and consisted mostly of exaggerated pharmacodynamic effects on the CNS. No genotoxic or carcinogenic effects were observed in vivo, and LCM showed a favorable profile in reproductive and developmental animal studies. Currently, LCM is in a late stage of clinical development as an adjunctive treatment for patients with uncontrolled partial‐onset seizures, and it is being assessed as monotherapy in patients with painful diabetic neuropathy. Further trials to identify LCM's potential in pain and for other indications have been initiated.

Keywords: Analgesics, Anticonvulsants, Epilepsy, Lacosamide, Neuropathic pain

Full Text

The Full Text of this article is available as a PDF (375.8 KB).

REFERENCES

  1. Backonja M, Beydoun A, Edwards KR, Schwartz SL, Fonseca V, Hes M, LaMoreaux L, Garofalo E (1998) Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: A randomized controlled trial. JAMA 280:1831–1836. [DOI] [PubMed] [Google Scholar]
  2. Barton ME, Klein BD, Wolf HH, White HS (2001) Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy. Epilepsy Res 47:217–227. [DOI] [PubMed] [Google Scholar]
  3. Bausch SB (2005) Axonal sprouting of GABAergic interneurons in temporal lobe epilepsy. Epilepsy Behav 7:390–400. [DOI] [PubMed] [Google Scholar]
  4. Ben‐Menachem E, Biton V, Jatuzis D, Abou‐Khalil B, Doty P, Rudd GD (2005) Efficacy and safety of adjunctive oral lacosamide for the treatment of partial onset seizures in patients with epilepsy. Epilepsia 57:30. [DOI] [PubMed] [Google Scholar]
  5. Beyreuther B, Callizot N, Stohr T (2006) Antinociceptive efficacy of lacosamide in a rat model for painful diabetic neuropathy. Eur J Pharmacol 539:64–70. [DOI] [PubMed] [Google Scholar]
  6. Bhalla TN, Tangri KK (1970) The time course of the carrageenan‐induced oedema of the paw of the rat. J Pharm Pharmacol 22:721. [DOI] [PubMed] [Google Scholar]
  7. Binder DK (2004) The role of BDNF in epilepsy and other diseases of the mature nervous system. Adv Exp Med Biol 548:34–56. [DOI] [PubMed] [Google Scholar]
  8. Biton V, Rosenfeld W, Whitesides J, Sommerville K (2005) Safety and tolerability of intravenous lacosamide as replacement for oral lacosamide in subjects with partial‐onset seizures. Epilepsia 120:258. [DOI] [PubMed] [Google Scholar]
  9. Bittigau P, Sifringer M, Genz K, Reith E, Pospischil D, Govindarajalu S, Dzietko M, Pesditschek S, Mai I, Dikranian K, et al. (2002) Antiepileptic drugs and apoptotic neurodegeneration in the developing brain. Proc Natl Acad Sci USA 99:15089–15094. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Bittigau P, Sifringer M, Genz K, Ikonomidou C (2003) Antiepileptic drugs and apoptosis in the developing brain. Ann N Y Acad Sci 993:103–114. [DOI] [PubMed] [Google Scholar]
  11. Blackburn‐Munro G, Ibsen N, Erichsen HK (2002) A comparison of the anti‐nociceptive effects of voltage‐activated Na+ channel blockers in the formalin test. Eur J Pharmacol 445:231–238. [DOI] [PubMed] [Google Scholar]
  12. Blair NT, Bean BP (2003) Role of tetrodotoxin‐resistant Na+ current slow inactivation in adaptation of action potential firing in small‐diameter dorsal root ganglion neurons. J Neurosci 23:10338–10350. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Borowicz KK, Gasior M, Kleinrok Z, Czuczwar SJ (1997) Influence of isradipine, niguldipine and dantrolene on the anticonvulsive action of conventional antiepileptics in mice. Eur J Pharmacol 323:45–51. [DOI] [PubMed] [Google Scholar]
  14. Boucher TJ, McMahon SB (2001) Neurotrophic factors and neuropathic pain. Curr Opin Pharmacol 1:66–72. [DOI] [PubMed] [Google Scholar]
  15. Boulton AJ (2003) Treatment of symptomatic diabetic neuropathy. Diabetes Metab Res Rev 19:S16–S21. [DOI] [PubMed] [Google Scholar]
  16. Brandt C, Heile A, Potschka H, Stöhr T, Löscher W. Effects of the novel antiepileptic drug lacosamide on the development of amygdala kindling in rats. Epilepsia 47:1803–1809. [DOI] [PubMed] [Google Scholar]
  17. Bretin S, Rogemond V, Marin P, Maus M, Torrens Y, Honnorat J, Glowinski J, Premont J, Gauchy C (2006) Calpain product of WT‐CRMP2 reduces the amount of surface NR2B NMDA receptor subunit. J Neurochem 98:1252–1265. [DOI] [PubMed] [Google Scholar]
  18. Cavazos JE, Cross DJ (2006) The role of synaptic reorganization in mesial temporal lobe epilepsy. Epilepsy Behav 8:483–493. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Chevrier P, Vijayaragavan K, Chahine M (2004) Differential modulation of Nav1.7 and Nav1.8 peripheral nerve sodium channels by the local anesthetic lidocaine. Br J Pharmacol 142:576–584. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Czech T, Yang JW, Csaszar E, Kappler J, Baumgartner C, Lubec G (2004) Reduction of hippocampal collapsin response mediated protein‐2 in patients with mesial temporal lobe epilepsy. Neurochem Res 29:2189–2196. [DOI] [PubMed] [Google Scholar]
  21. D'Amour FE, Smith DL (1941) A method of determining loss of pain sensation. J Pharmacol Exp Ther 72:74–79. [Google Scholar]
  22. Danielsson BR, Lansdell K, Patmore L, Tomson T (2003) Phenytoin and phenobarbital inhibit human HERG potassium channels. Epilepsy Res 55:147–157. [DOI] [PubMed] [Google Scholar]
  23. Danielsson BR, Lansdell K, Patmore L, Tomson T (2005) Effects of the antiepileptic drugs lamotrigine, topiramate and gabapentin on hERG potassium currents. Epilepsy Res 63:17–25. [DOI] [PubMed] [Google Scholar]
  24. Devor M (2006) Sodium channels and mechanisms of neuropathic pain. J Pain 7:3–12. [DOI] [PubMed] [Google Scholar]
  25. Dubuisson D, Dennis SG (1977) The formalin test: A quantitative study of the analgesic effects of morphine, and brain stem stimulation in rats and cats. Pain 4:161–174. [DOI] [PubMed] [Google Scholar]
  26. Eisenberg E, Lurie Y, Braker C, Daoud D, Ishay A (2001) Lamotrigine reduces painful diabetic neuropathy: A randomized, controlled study. Neurology 57:505–509. [DOI] [PubMed] [Google Scholar]
  27. Errington AC, Coyne L, Stohr T, Selve N, Lees G (2006) Seeking a mechanism of action for the novel anticonvulsant lacosamide. Neuropharmacology 50:1016–1029. [DOI] [PubMed] [Google Scholar]
  28. Fleidervish IA, Friedman A, Gutnick MJ (1996) Slow inactivation of Na+ current and slow cumulative spike adaptation in mouse and guinea‐pig neocortical neurones in slices. J Physiol 493:83–97. Erratum in: J Physiol 494:907. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Field MJ, Oles RJ, Lewis AS, McCleary S, Hughes J, Singh L (1997) Gabapentin (neurontin) and S‐(+)‐3‐isobutylgaba represent a novel class of selective antihyperalgesic agents. Br J Pharmacol 121:1513–1522. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Gimbel JS, Richards P, Portenoy RK (2003) Controlled‐release oxycodone for pain in diabetic neuropathy: A randomized controlled trial. Neurology 60:927–934. [DOI] [PubMed] [Google Scholar]
  31. Glier C, Dzietko M, Bittigau P, Jarosz B, Korobowicz E, Ikonomidou C (2004) Therapeutic doses of topiramate are not toxic to the developing rat brain. Exp Neurol 187:403–409. [DOI] [PubMed] [Google Scholar]
  32. Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S (2005) Duloxetine vs placebo in patients with painful diabetic neuropathy. Pain 116:109–118. [DOI] [PubMed] [Google Scholar]
  33. Hao J, Stöhr T, Selve N, Wiesenfeld‐Hallin Z, Xu X (2006) Lacosamide, a new anti‐epileptic, alleviates neuropathic pain‐like behaviors in rat models of spinal cord or trigeminal nerve injury. Eur J Pharmacol 553:135–140. [DOI] [PubMed] [Google Scholar]
  34. Herman ST, Pedley TA (1998) New options for the treatment of epilepsy. JAMA 280:693–694. [DOI] [PubMed] [Google Scholar]
  35. Hidvégi T, Bretschneider M, Bongardt S, Koch B (2006) Lacosamide in subjects with painful distal diabetic neuropathy: Results of a multi‐center, randomized, double‐blind, placebo‐controlled, parallel‐group trial. J Pain 7:45. [Google Scholar]
  36. Hönack D, Löscher W (1995) Kindling increases the sensitivity of rats to adverse effects of certain antiepileptic drugs. Epilepsia 36:763–771. [DOI] [PubMed] [Google Scholar]
  37. Honerjäger P (1986) The contribution of Na channel block to the negative inotropic effect of antiarrhythmic drugs. Basic Res Cardiol 81:33–37. [DOI] [PubMed] [Google Scholar]
  38. Honerjäger P, Loibl E, Steidl I, Schonsteiner G, Ulm K (1986) Negative inotropic effects of tetrodotoxin and seven class 1 antiarrhythmic drugs in relation to sodium channel blockade. Naunyn Schmiedeberg's Arch Pharmacol 332:184–195. [DOI] [PubMed] [Google Scholar]
  39. Hurley RW, Chatterjea D, Rose Feng M, Taylor CP, Hammond DL (2002) Gabapentin and pregabalin can interact synergistically with naproxen to produce antihyperalgesia. Anesthesiology 97:1263–1273. [DOI] [PubMed] [Google Scholar]
  40. Kobayashi M, Wen X, Buckmaster PS (2003) Reduced inhibition and increased output of layer II neurons in the medial entorhinal cortex in a model of temporal lobe epilepsy. J Neurosci 23:8471–8479. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Löscher W (1999) Animal models of epilepsy and epileptic seizures In: Eadie MJ, Vajda FJ, editors. Antiepileptic drugs, pharmacology, and therapeutics, handbook of experimental pharmacology. Berlin , Germany , Springer Verlag, pp. 19–62. [Google Scholar]
  42. Luszczki JJ, Andres MM, Czuczwar P, Cioczek‐Czuczwar A, Wojcik‐Cwikla J, Ratnaraj N, Patsalos PN, Czczwar SJ (2005) Levetiracetam selectively potentiates the acute neurotoxic effects of topiramate and carbamazepine in the rotarod test in mice. Eur Neuropsychopharmacol 15:609–616. [DOI] [PubMed] [Google Scholar]
  43. Manthey D, Asimiadou S, Stefovska V, Kaindl AM, Fassbender J, Ikonomidou C, Bittigau P (2005) Sulthiame but not levetiracetam exerts neurotoxic effect in the developing rat brain. Exp Neurol 193:497–503. [DOI] [PubMed] [Google Scholar]
  44. Max MB, Lynch SA, Muir J, Shoaf SE, Smoller B, Dubner R (1992) Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med 326:1250–1256. [DOI] [PubMed] [Google Scholar]
  45. McCleane G, Koch B, Rauschkolb C (2003) Does lacosamide have an analgesic effect in human neuropathic pain? An open label study. Neurosci Lett 352:117–120. [DOI] [PubMed] [Google Scholar]
  46. McQuay HJ, Tramer M, Nye BA, Carroll D, Wiffen PJ, Moore RA (1996) A systematic review of antidepressants in neuropathic pain. Pain 68:217–227. [DOI] [PubMed] [Google Scholar]
  47. Melzack R, Coderre TJ, Katz J, Vaccarino AL (2001) Central neuroplasticity and pathological pain. Ann N Y Acad Sci 933:157–174. [DOI] [PubMed] [Google Scholar]
  48. Mestre M, Djellas Y, Carriot T, Cavero I (2000) Frequency‐independent blockade of cardiac Na+ channels by riluzole: Comparison with established anticonvulsants and class I anti‐arrhythmics. Fundam Clin Pharmacol 14:107–117. [DOI] [PubMed] [Google Scholar]
  49. Mickus T, Jung H, Spruston N (1999) Properties of slow, cumulative sodium channel inactivation in rat hippocampal CA1 pyramidal neurons. Biophys J 76:846–860. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Morrow TJ, Agacinski S, Polen D, Swindell MK, Selve N (2001) Antinociceptive properties of the anticonvulsant SPM 927 (harkoseride) in rat Soc Neurosci abstract no. 508.16.2001. [Google Scholar]
  51. Nagakura Y, Okada M, Kohara A, Kiso T, Toya T, Iwai A, Wanibuchi F, Yamaguchi T (2003) Allodynia and hyperalgesia in adjuvant‐induced arthritic rats: Time course of progression and efficacy of analgesics. J Pharmacol Exp Ther 306:490–497. [DOI] [PubMed] [Google Scholar]
  52. Ness TJ, Gebhart GF (1986) Centrifugal modulation of the rat tail flick reflex evoked by graded noxious heating of the tail. Brain Res 386:41–52. [DOI] [PubMed] [Google Scholar]
  53. Patel S, Naeem S, Kesingland A, Froestl W, Capogna M, Urban L, Fox A (2001) The effects of GABA(B) agonists and gabapentin on mechanical hyperalgesia in models of neuropathic and inflammatory pain in the rat. Pain 90:217–226. [DOI] [PubMed] [Google Scholar]
  54. Perucca E (1996) Established antiepileptic drugs. Baillière's Clin Neurol 5:693–722. [PubMed] [Google Scholar]
  55. Perucca E, Gram L, Avanzini G, Dulac O (1998) Antiepileptic drugs as a cause of worsening seizures. Epilepsia 39:5–17. [DOI] [PubMed] [Google Scholar]
  56. Pezet S, McMahon SB (2006) Neurotrophins: Mediators and modulators of pain. Annu Rev Neurosci 29:507–538. [DOI] [PubMed] [Google Scholar]
  57. Regnier J (1929) Méthode de mesure des anesthesiques locaux. Thèse Doct. Méd., St Dizier , France .
  58. Rogawski MA, Löscher W (2004) The neurobiology of antiepileptic drugs. Nat Rev Neurosci 5:553–564. [DOI] [PubMed] [Google Scholar]
  59. Rosenfeld W, Biton V, Mameniskiene R, Vaiciene N, Whitesides J, Shiltmeyer B, Sommerville K. (2005) Pharmacokinetics and safety of intravenous lacosamide administered as replacement for adjunctive oral lacosamide in patients with partial‐onset seizures. Epilepsia 184:2.278. [Google Scholar]
  60. Rosenstock J, Tuchman M, LaMoreaux L, Sharma U (2004) Pregabalin for the treatment of painful diabetic peripheral neuropathy: A double‐blind, placebo‐controlled trial. Pain 110:628–638. [DOI] [PubMed] [Google Scholar]
  61. Sander JW (1998) New drugs for epilepsy. Curr Opin Neurol 11:141–148. [DOI] [PubMed] [Google Scholar]
  62. Sazgar M, Bourgeois BF (2005) Aggravation of epilepsy by antiepileptic drugs. Pediatr Neurol 33:227–234. [DOI] [PubMed] [Google Scholar]
  63. Sindrup SH, Jensen TS (1999) Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain 83:389–400. [DOI] [PubMed] [Google Scholar]
  64. Singh L, Field MJ, Ferris P, Hunter JC, Oles RJ, Williams RG, Woodruff GN (1996) The antiepileptic agent gabapentin (Neurontin) possesses anxiolytic‐like and antinociceptive actions that are reversed by D‐serine. Psychopharmacology 127:1–9. [DOI] [PubMed] [Google Scholar]
  65. Shaibani A, Kenney P, Simpson J, Bongardt S (2006) Lacosamide in subjects with painful distal diabetic neuropathy: Results of a multi‐center, open‐label, follow‐on trial. J Pain 7:43. 16414554 [Google Scholar]
  66. Stohr T, Krause E, Selve N (2006) Lacosamide displays potent antinociceptive effects in animal models for inflammatory pain. Eur J Pain 10:241–249. [DOI] [PubMed] [Google Scholar]
  67. Stohr T, Kupferberg HJ, Stables JP, Choi D, Harris RH, Kohn H, Walton N, White S (2007) Lacosamide, a novel anticonvulsant drug, shows efficacy with a wide safety margin in rodent models for epilepsy. Epilepsy Res ; Submitted. [DOI] [PubMed] [Google Scholar]
  68. Swinyard EA, Brown WC, Goodman LS (1952) Comparative assays of antiepileptic drugs in mice and rats. J Pharmacol Exp Ther 106:319–330. [PubMed] [Google Scholar]
  69. Tjolsen A, Berge OG, Hunskaar S, Rosland JH, Hole K (1992) The formalin test: An evaluation of the method. Pain 51:5–17. [DOI] [PubMed] [Google Scholar]
  70. Tongiorgi E, Domenici L, Simonato M (2006) What is the biological significance of BDNF mRNA targeting in the dendrites? Clues from epilepsy and cortical development. Mol Neurobiol. 33:17–32. [DOI] [PubMed] [Google Scholar]
  71. Villetti G, Bergamaschi M, Bassani F, Bolzoni PT, Maiorino M, Pietra C, Rondelli I, Chamiot‐Clerc P, Simonato M, Barbieri M (2003) Antinociceptive activity of the N‐methyl‐D‐aspartate receptor antagonist N‐(2‐Indanyl)‐glycinamide hydrochloride (CHF3381) in experimental models of inflammatory and neuropathic pain. J Pharmacol Exp Ther 306:804–814. [DOI] [PubMed] [Google Scholar]
  72. Webster R, Leishman D, Walker D (2002) Towards a drug concentration effect relationship for QT prolongation and torsades de pointes. Curr Opin Drug Discov Devel 5:116–126. [PubMed] [Google Scholar]
  73. Wymer J, Garrison C, Simpson J, Koch B (2006) A multicenter, randomized, double‐blind, placebo‐controlled trial to assess the efficacy and safety of lacosamide in subjects with painful distal diabetic neuropathy. Neurology 66:A202. [Google Scholar]
  74. Yamaguchi T (2003) Allodynia and hyperalgesia in adjuvant‐induced arthritic rats: Time course of progression and efficacy of analgesics. J Pharmacol Exp Ther 306:490–497. [DOI] [PubMed] [Google Scholar]
  75. Yoshimura T, Kawano Y, Arimura N, Kawabata S, Kikuchi A, Kaibuchi K (2005) GSK‐3beta regulates phosphorylation of CRMP‐2 and neuronal polarity. Cell 120:137–149. [DOI] [PubMed] [Google Scholar]

Articles from CNS Drug Reviews are provided here courtesy of Wiley

RESOURCES